HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Influence of hypersulfated and low molecular weight heparins on ischemia/reperfusion: injury and allograft rejection in rat kidneys.

Abstract
The aim of the study was to evaluate the effect of the hypersulfated nonanticoagulant heparin derivative LU 51198 (LU) and of the low molecular weight heparin reviparin (REVI) on ischemia/reperfusion (I/R) injury, acute rejection (AR) and chronic allograft nephropathy (CAN) in rats. Organs were harvested 5 days after 60 min of renal I/R injury. For investigation of AR and CAN we used the allogeneic Fisher-Lewis model. Kidneys were harvested at one respectively 32 weeks after transplantation. Rats were treated with either vehicle, LU or REVI. After I/R injury, treatment with REVI or LU reduced infiltration with MHC II and R73-positive cells, whereas only REVI reduced ED1-positive cells and expression of monocyte chemoattractant protein-1. There was no effect of REVI and LU on acute allograft rejection. Treatment with LU or REVI reduced glomerular infiltration with ED1 and MHCII-positive cells and renal expression of transforming growth factor-beta 32 weeks after transplantation. Only REVI treatment reduced albuminuria, interstitial infiltration and histological signs of CAN. LU, and in a more potent manner REVI, reduce signs of CAN and renal inflammation after I/R injury. Chemically modified heparins without anticoagulatory effects may offer a new treatment option in preventing I/R injury and CAN in human kidney transplantation.
AuthorsUwe Gottmann, Astrid Mueller-Falcke, Peter Schnuelle, Rainer Birck, Volker Nickeleit, Fokko J van der Woude, Benito A Yard, Claude Braun
JournalTransplant international : official journal of the European Society for Organ Transplantation (Transpl Int) Vol. 20 Issue 6 Pg. 542-9 (Jun 2007) ISSN: 0934-0874 [Print] Switzerland
PMID17355246 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • LU 51198
  • reviparin
  • Heparin
Topics
  • Albuminuria (drug therapy, prevention & control)
  • Animals
  • Anticoagulants (therapeutic use)
  • Graft Rejection (drug therapy)
  • Heparin (analogs & derivatives, therapeutic use)
  • Heparin, Low-Molecular-Weight (therapeutic use)
  • Humans
  • Kidney (pathology)
  • Male
  • Rats
  • Rats, Inbred F344
  • Rats, Inbred Lew
  • Reperfusion Injury (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: